TNF and polyarticular juvenile idiopathic arthritis: Among the TNF-α inhibitors analyzed, adalimumab [11], certolizumab [12], and etanercept [13] are approved by the FDA for polyarticular JIA in patients aged ≥2 years, while infliximab [14] is approved for pediatric Crohn’s disease in children ≥6 years.